Rebiotix said Monday that it has closed $25 million in Series B Funding. The investors were not named. Based in Roseville, Minn., Rebiotix is a biotechnology company focused on treating gastrointestinal diseases.

from PE Hub Blog http://ift.tt/1qM636X
via IFTTT

Publicités